GAJ - HEP DART 2011 Presentations





		HEP DART 2011 Frontiers in Drug Development for Viral Hepatitis to view the complete abstract book Selected Slide Presentations Click on the links below to view presentations. Burden of Hepatitis Viruses, Natural History and Management Impact and implementation of the WHO resolution for viral hepatitis Steve Wiersma, WHO, Switzerland Addressing an epidemic: San Francisco Hep B Free Janet Zola, San Francisco Department of Public Health, USA Identification, screening and surveillance of HCV infection in the era of improved therapy for hepatitis C John Ward, Centers for Disease Control and Prevention, USA Discoveries and Advances in HCV Research William H. Prusoff HEP DART Lifetime Achievement Award Lecture The golden age of hepatitis research: a jaundiced view of history Robert Purcell, NIAID, National Institutes of Health, USA Clinical efficacy of HCV NS5A inhibitors Anna Lok, University of Michigan Medical Center, USA State of the Art Presentation Exploitation of host cell targets for HCV-specific therapy Ralf Bartenschlager, University of Heidelberg, Germany New Targets: Cellular Systems and Infectious Models State of the Art Presentation New in vitro and in vivo preclinical models for HCV drug discovery Charles Rice, The Rockefeller University, USA Management of Hepatitis Infections and Genetic Markers Host genetics and the outcome of hepatitis C infection and its treatment David Thomas, Johns Hopkins University School of Medicine, USA Emergence, Re-emergence, Resistance, Prevention and Eradication of Hepatitis Viruses State of the Art Presentation HBV and HCV antiviral drug resistance: prevention and monitoring Stephen Locarnini, Victorian Infectious Diseases Reference Laboratory, Australia Eradication of HBV: can we eliminate cccDNA? Massimo Levrero, Sapienza Università di Roma, Italy Special Lecture Hepatitis delta virus and its re-emergence John Taylor, Fox Chase Cancer Center, USA Clinical Trial Design Management of hepatitis C in the era of DAA: lessons learned from failed studies Paul Pockros, The Scripps Clinic, USA Boceprevir and telaprevir: benefits and limitations Jules Dienstag, Harvard Medical School, USA Will lambda interferon replace pegylated interferon? Douglas Dieterich, Mount Sinai School of Medicine, USA New Targets: Insights into Drug Mechanisms Autophagy machinery is required to initiate hepatitis C virus replication Marlène Dreux, The Scripps Research Institute, USA Antiviral HBV Assembly Effectors (AEs): mechanisms and implications for eradication Adam Zlotnick, Indiana University, USA TLR7: a therapeutic target for HBV and HCV chronic infections Robert Lanford, Texas Biomedical Research Institute, USA Pan Genotypic Therapies for Hepatitis Infections and Diagnosis State of the Art Presentation The future of HCV therapy in non-genotype 1 patients Marc Bourlière, Hôpital Saint Joseph, France Safety and efficacy of PR+DAA in HCV/HIV co-infected patients Mark Sulkowski, Johns Hopkins University, USA State of the Art Presentation Hepatitis C and the brain Howard Thomas, Imperial College, UK Co-infections, Therapeutic Modalities and Regulatory Issues: Dangerous Liaisons Acute hepatitis C infection in HIV-infected patients Ken Sherman, University of Cincinnati College of Medicine, USA HIV/HCV co-infected people: what are the specific concerns co-infected people face? Marion Peters, University of California, San Francisco, USA Consensus recommendation on treatment of acute HCV in HIV+ people, ideas for trials Jürgen Rockstroh, University of Bonn, Germany Immunological Approaches, Vaccines and Virus-host Interactions Intrinsic innate immunity and HCV infection T. Jake Liang, NIDDK, National Institutes of Health, USA Liver Damage: Decompensation, Fibrosis, Hepatocellular Carcinoma and Diagnostics State of the Art Presentation Best targets for antifibrotic therapy Scott Friedman, Mount Sinai School of Medicine, USA The role of direct-acting antiviral agents in patients with cirrhosis Ira Jacobson, Weill Cornell Medical College, USA Special Lecture Mechanism of action of nitazoxanide Brent Korba, Georgetown University, USA Oral Abstract Presentations Safety of telaprevir or boceprevir in combination with peginterferon alfa/ribavirin, in cirrhotic non responders. First results of the French Early Access Program (ANRS CO20-CUPIC) in real-life setting Marc Bourlière, Hôpital Saint Joseph, France Alisporivir plus PegIFNalfa2a/Ribavirin treatment for chronic hepatitis C genotype (GT) 1 treatment naïve patients shows superior sustained virologic response irrespective of IL28B genotype and high barrier to resistance Robert Flisiak, Medical University of Bialystok, Poland Safety and antiviral activity of MK-5172, a next generation HCV NS3/4A protease inhibitor with a broad HCV genotypic activity spectrum and potent activity against known resistance mutants, in genotype-1 and -3 HCV-infected patients Iain Fraser, Merck & Co. Inc., USA Contribution of a mutational bias in HCV replication to the genetic barrier in the development of drug resistance Matthias Götte, McGill University, Canada PSI-7977 400 mg with PEG/RBV provides 93% SVR across HCV GT 1, 2, 3 Eric Lawitz, Alamo Medical Research, USA Informational Talk: The Coalition to Eradicate Viral Hepatitis in Asia Pacific (CEVHAP): strategic public policy development for the control of viral hepatitis Stephen Locarnini, Victorian Infectious Diseases Reference Laboratory, Australia Informational Talk: HCV-TARGET, the hepatitis C therapeutic registry and research network for novel clinical and translational studies David Nelson, University of Florida, USA Characterization of 2'-C-methyl C-nucleoside HCV polymerase inhibitors Adrian Ray, Gilead Sciences, Inc., USA Antiviral activity and tolerability of BIT225 plus pegylated interferon alpha 2a or 2b and weight-based ribavirin for 28 days in HCV treatment-naïve monoinfected patients Tawesak Tanwandee, Siriraj Hospital/Mahidol University, Thailand